Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

VISTA: A Mediator of Quiescence and a Promising Target in Cancer Immunotherapy
Long Yuan, Jahnavi Tatineni, Kathleen M. Mahoney, et al.
Trends in Immunology (2021) Vol. 42, Iss. 3, pp. 209-227
Open Access | Times Cited: 159

Showing 1-25 of 159 citing articles:

Immune checkpoint therapy—current perspectives and future directions
Padmanee Sharma, Sangeeta Goswami, Deblina Raychaudhuri, et al.
Cell (2023) Vol. 186, Iss. 8, pp. 1652-1669
Closed Access | Times Cited: 477
Tumor cells dictate anti-tumor immune responses by altering pyruvate utilization and succinate signaling in CD8+ T cells
Ilaria Elia, Jared H. Rowe, Sheila Johnson, et al.
Cell Metabolism (2022) Vol. 34, Iss. 8, pp. 1137-1150.e6
Open Access | Times Cited: 176
Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts
Yuchen Wang, Hao Zhang, Chao Liu, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 176
Methionine deficiency facilitates antitumour immunity by altering m6A methylation of immune checkpoint transcripts
Ting Li, Yue‐Tao Tan, Yan‐Xing Chen, et al.
Gut (2022) Vol. 72, Iss. 3, pp. 501-511
Open Access | Times Cited: 120
Immune checkpoint proteins: Signaling mechanisms and molecular interactions in cancer immunotherapy
Shreyas Gaikwad, Manas Yogendra Agrawal, Itishree Kaushik, et al.
Seminars in Cancer Biology (2022) Vol. 86, pp. 137-150
Closed Access | Times Cited: 115
Signaling pathways and targeted therapies in lung squamous cell carcinoma: mechanisms and clinical trials
Zhenyi Niu, Runsen Jin, Yan Zhang, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 95
Exploiting innate immunity for cancer immunotherapy
Ming Yi, Tianye Li, Mengke Niu, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 85
Recent Advances and Challenges in Cancer Immunotherapy
Chelsea Peterson, Nathan Denlinger, Yiping Yang
Cancers (2022) Vol. 14, Iss. 16, pp. 3972-3972
Open Access | Times Cited: 82
Evolution of immune and stromal cell states and ecotypes during gastric adenocarcinoma progression
Ruiping Wang, Shumei Song, Jiang‐Jiang Qin, et al.
Cancer Cell (2023) Vol. 41, Iss. 8, pp. 1407-1426.e9
Open Access | Times Cited: 75
The role of PD-1 signaling in health and immune-related diseases
Ruyue Chen, Yun Zhu, Yunyan Shen, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 58
Eliminating a barrier: Aiming at VISTA, reversing MDSC-mediated T cell suppression in the tumor microenvironment
Yayuan Deng, Mengjia Shi, Yi Lin, et al.
Heliyon (2024) Vol. 10, Iss. 17, pp. e37060-e37060
Open Access | Times Cited: 37
The B7:CD28 family and friends: Unraveling coinhibitory interactions
Kelly P. Burke, Apoorvi Chaudhri, Gordon J. Freeman, et al.
Immunity (2024) Vol. 57, Iss. 2, pp. 223-244
Open Access | Times Cited: 32
Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities
Nanhao Yin, Xintong Li, Xuanwei Zhang, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 20
Immune Checkpoint Inhibitors in Cancer Therapy—How to Overcome Drug Resistance?
Yefang Lao, Daoming Shen, Weili Zhang, et al.
Cancers (2022) Vol. 14, Iss. 15, pp. 3575-3575
Open Access | Times Cited: 52
Emerging Trends in Immunotherapy for Cancer
Alok Mishra, Amjad Ali, Shubham Dutta, et al.
Diseases (2022) Vol. 10, Iss. 3, pp. 60-60
Open Access | Times Cited: 46
CD39 inhibition and VISTA blockade may overcome radiotherapy resistance by targeting exhausted CD8+ T cells and immunosuppressive myeloid cells
Yuhan Zhang, Junyi Hu, Kai Ji, et al.
Cell Reports Medicine (2023) Vol. 4, Iss. 8, pp. 101151-101151
Open Access | Times Cited: 27
VISTA and its ligands: the next generation of promising therapeutic targets in immunotherapy
Najibeh Shekari, Dariush Shanehbandi, Tohid Kazemi, et al.
Cancer Cell International (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 26
Compartmentalized spatial profiling of the tumor microenvironment in head and neck squamous cell carcinoma identifies immune checkpoint molecules and tumor necrosis factor receptor superfamily members as biomarkers of response to immunotherapy
Habib Sadeghirad, Ning Liu, James Monkman, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 25
VISTA expression and patient selection for immune-based anticancer therapy
Alexander S. Martin, Michael Molloy, Andrey Ugolkov, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 24
Targeting STAT3-VISTA axis to suppress tumor aggression and burden in acute myeloid leukemia
Jianshan Mo, Linhong Deng, Keren Peng, et al.
Journal of Hematology & Oncology (2023) Vol. 16, Iss. 1
Open Access | Times Cited: 24
Cancer immune evasion through KRAS and PD-L1 and potential therapeutic interventions
Alex Watterson, Matthew A. Coelho
Cell Communication and Signaling (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 24
Targeting conserved TIM3 + VISTA + tumor-associated macrophages overcomes resistance to cancer immunotherapy
Isaure Vanmeerbeek, Stefan Naulaerts, Jenny Sprooten, et al.
Science Advances (2024) Vol. 10, Iss. 29
Open Access | Times Cited: 15
Therapeutic and immunomodulatory potentials of mesenchymal stromal/stem cells and immune checkpoints related molecules
Ali Hazrati, Kosar Malekpour, Hossein Khorramdelazad, et al.
Biomarker Research (2024) Vol. 12, Iss. 1
Open Access | Times Cited: 13
VISTA checkpoint inhibition by pH-selective antibody SNS-101 with optimized safety and pharmacokinetic profiles enhances PD-1 response
Thomas Thisted, F. Donelson Smith, Arnab Mukherjee, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 11
Viewing the immune checkpoint VISTA: landscape and outcomes across cancers
Daisuke Nishizaki, Razelle Kurzrock, Hirotaka Miyashita, et al.
ESMO Open (2024) Vol. 9, Iss. 4, pp. 102942-102942
Open Access | Times Cited: 10
Page 1 - Next Page

Scroll to top